Cetylpyridinium Chloride

西吡氯铵

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameCetylpyridinium Chloride
Drug Alias NameCPC nanoemulsionCetylpyridinii chloridumCetylpyridinium nanoemulsionNanotxtNB-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell membrane modulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursPremature Birth +[14] 
Global Approved IndicationsStomatitisTonsillitisPharyngitis +[4] 
Approved Indications in ChinaInfections
Original Approved Country/TerritoryJapan
Original Approved Date1970/03/31
Country/TerritoryCanadaUnited StatesMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesNeoLogics Bioscience Co LtdJohns Hopkins Bloomberg School Of Public Health
Inactive CompaniesNanobio CoUniversity Of California San FranciscoThe University Of Toledo Health Science Campus +[4] 
Active IndicationsSolid tumoursPremature BirthObstetric Labor, Premature +[8] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Pharyngeal DiseasesCoronavirus Infections +[6] 

Other Information

ATC CodeB05CA01D08AJ03D09AA07 +[4] 
Related LinksKEGG